These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 21691749)
1. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. Zhang Y; Yao L; Zhang X; Ji H; Wang L; Sun S; Pang D J Cancer Res Clin Oncol; 2011 Aug; 137(8):1245-53. PubMed ID: 21691749 [TBL] [Abstract][Full Text] [Related]
2. Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma. Wang Z; Zhu L; Guo T; Wang Y; Yang J Hum Pathol; 2015 Jul; 46(7):1006-14. PubMed ID: 25971547 [TBL] [Abstract][Full Text] [Related]
3. USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. Piao S; Liu Y; Hu J; Guo F; Ma J; Sun Y; Zhang B PLoS One; 2012; 7(8):e42540. PubMed ID: 22880026 [TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Yang M; Liu YD; Wang YY; Liu TB; Ge TT; Lou G Tumour Biol; 2014 Feb; 35(2):929-34. PubMed ID: 23979981 [TBL] [Abstract][Full Text] [Related]
5. USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. Li J; Wang Z; Li Y J Cancer Res Clin Oncol; 2012 Aug; 138(8):1291-7. PubMed ID: 22447106 [TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma. Dai W; Yao Y; Zhou Q; Sun CF PLoS One; 2014; 9(1):e87148. PubMed ID: 24466336 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Wang H; Li YP; Chen JH; Yuan SF; Wang L; Zhang JL; Yao Q; Li NL; Bian JF; Fan J; Yi J; Ling R Tumour Biol; 2013 Jun; 34(3):1635-9. PubMed ID: 23412977 [TBL] [Abstract][Full Text] [Related]
8. High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Tang B; Tang F; Li B; Yuan S; Xu Q; Tomlinson S; Jin J; Hu W; He S Oncotarget; 2015 May; 6(14):12654-67. PubMed ID: 25909224 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Ning J; Zhang J; Liu W; Lang Y; Xue Y; Xu S Eur J Histochem; 2012 Nov; 56(4):e46. PubMed ID: 23361242 [TBL] [Abstract][Full Text] [Related]
10. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues. Cao L; Sun PL; Yao M; Jia M; Gao H Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Piao S; Ma J; Wang W; Liu Y; Zhang M; Chen H; Guo F; Zhang B; Guo F Oral Oncol; 2013 Aug; 49(8):796-801. PubMed ID: 23664741 [TBL] [Abstract][Full Text] [Related]
12. Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma. Tang B; Liang X; Tang F; Zhang J; Zeng S; Jin S; Zhou L; Kudo Y; Qi G Int J Oncol; 2015 Dec; 47(6):2208-16. PubMed ID: 26497847 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma. Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477 [TBL] [Abstract][Full Text] [Related]
14. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458 [TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-specific protease 22 is associated with poor prognosis in neuroblastoma. Zhibo Q; Lianxin L Adv Clin Exp Med; 2020 Mar; 29(3):295-300. PubMed ID: 32216173 [TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics. Liang J; Zhang X; Xie S; Zhou X; Shi Q; Hu J; Wang W; Qi W; Yu R Med Oncol; 2014 Apr; 31(4):899. PubMed ID: 24573640 [TBL] [Abstract][Full Text] [Related]
17. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Alford SH; Toy K; Merajver SD; Kleer CG Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565 [TBL] [Abstract][Full Text] [Related]
18. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma. Ning Z; Wang A; Liang J; Xie Y; Liu J; Feng L; Yan Q; Wang Z Int J Oncol; 2014 Oct; 45(4):1594-608. PubMed ID: 24993031 [TBL] [Abstract][Full Text] [Related]
19. Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. Möllerström E; Kovács A; Lövgren K; Nemes S; Delle U; Danielsson A; Parris T; Brennan DJ; Jirström K; Karlsson P; Helou K BMC Cancer; 2010 Jun; 10():296. PubMed ID: 20553615 [TBL] [Abstract][Full Text] [Related]
20. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH Oncology; 2004; 66(6):429-38. PubMed ID: 15452371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]